Table 6.
Medications with no clinically meaningful interaction with one or more acid-reducing agents (n = 109)
| Acitretin | Donepezil | Lisdexamfetamine | Sertindole |
| Alectinib | Dronedarone | Lopinavir and ritonavir (Kaletra®) | Sildenafil |
| Ambrisentan | Duloxetine | Losartan | Sodium oxybate |
| Amlodipine | Efavirenz | Meloxicam | Sorafenib |
| Aripiprazole | Elbasvir and grazoprevir (Zepatier®) | Metronidazole | Sulfasalazine |
| Asenapine | Eliglustat | Moexipril | Sulindac |
| Aspirin | Eprosartan | Naproxen DR | Tapentadol |
| Aspirin/extended-release dipyridamole (Aggrenox®) | Etravirine | Nebivolol | Telithromycin |
| Axitinib | Ezetimibe | Nevirapine | Temozolomide |
| Azacitidine | Famciclovir | Nifedipine | Topotecan |
| Betrixaban | Febuxostat | Nintedanib | Tramadol |
| Boceprevir | Fenofibric acid | Obeticholic acid | Trandolapril |
| Bortezomib | Fenoprofen | Osimertinib | Ulipristal acetate |
| Brexpiprazole | Fluconazole | Oxcarbazepine | Valacyclovir |
| Cabozantinib | Fluvastatin | Palbociclib | Valproic acid |
| Carvedilol | Fosamprenavir | Paricalcitol | Valsartan |
| Cephalexin | Gabapentin | Pioglitazone | Vandetanib |
| Ceritinib | Gabapentin enacarbil | Piroxicam | Venlafaxine |
| Cobimetinib | Garenoxacin | Ponatinib | Vilazodone |
| Crizotinib | Glecaprevir/pibrentasvir (Mavyret™) | Posaconazole delayed release capsules | Vismodegib |
| Dabigatran etexilate mesylate | Glimepiride | Prasugrel | Vorapaxar |
| Danoprevir | Imatinib | Propranolol | Voriconazole |
| Dapsone | Indinavir | Raloxifene | Zolpidem |
| Darunavir | Isavuconazonium sulfate | Ramelteon | |
| Diazepam | Isoniazid | Repaglinide | |
| Diclofenac | Itraconazole oral suspension | Risperidone | |
| Digoxin | Lamotrigine | Rivaroxaban | |
| Divalproex | Letrozole | Saxagliptin |
Medications were identified via searches and screens of the PDR3D: Reed Tech Navigator™, University of Washington Drug–Drug Interaction Database (DIDB), and DailyMed databases as detailed in Sect. 4.1
DR delayed release